Kajal Rajput

3rd Milestone, Faridabad Gurgaon Expressway
Faridabad, HR 121001, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.

Journal: ACS pharmacology & translational science

Published: September 02, 2024

The mTORC2 subunit RICTOR drives breast cancer progression by promoting ganglioside biosynthesis through transcriptional and epigenetic mechanisms.

The mTORC2 subunit RICTOR drives breast cancer progression by promoting ganglioside biosynthesis through transcriptional and epigenetic mechanisms.

Journal: PLoS biology

Published: March 27, 2024

A localized hydrogel-mediated chemotherapy causes immunogenic cell death via activation of ceramide-mediated unfolded protein response.

A localized hydrogel-mediated chemotherapy causes immunogenic cell death via activation of ceramide-mediated unfolded protein response.

Journal: Science advances

Published: June 30, 2023

Targeting Vancomycin-Resistant Enterococci (VRE) Infections and Van Operon-Mediated Drug Resistance Using Dimeric Cholic Acid-Peptide Conjugates.

Targeting Vancomycin-Resistant Enterococci (VRE) Infections and Van Operon-Mediated Drug Resistance Using Dimeric Cholic Acid-Peptide Conjugates.

Journal: Journal of medicinal chemistry

Published: November 04, 2022

Unique sphingolipid signature identifies luminal and triple-negative breast cancer subtypes.

Unique sphingolipid signature identifies luminal and triple-negative breast cancer subtypes.

Journal: International journal of cancer

Published: October 21, 2022

Ceramide Kinase (CERK) Emerges as a Common Therapeutic Target for Triple Positive and Triple Negative Breast Cancer Cells.

Ceramide Kinase (CERK) Emerges as a Common Therapeutic Target for Triple Positive and Triple Negative Breast Cancer Cells.

Journal: Cancers

Published: July 09, 2022

Alternative splicing of CERS2 promotes cell proliferation and migration in luminal B subtype breast cancer cells.

Alternative splicing of CERS2 promotes cell proliferation and migration in luminal B subtype breast cancer cells.

Journal: Oncoscience

Published: March 31, 2021

Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype.

Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype.

Journal: Cell death & disease

Published: April 08, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026